102.64 +0.46 (0.45%)
Pre-Market: 4:27AM EST
|Bid||102.29 x 3200|
|Ask||102.44 x 2200|
|Day's Range||101.70 - 102.58|
|52 Week Range||84.65 - 105.08|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-0.23%|
|Beta (5Y Monthly)||0.86|
|Expense Ratio (net)||0.13%|
Yahoo Finance's Anjalee Khemlani sits down with Ambar Boodhoo, EY Americas Life Science Deals Leader, at the JPMorgan Chase Healthcare Conference to discuss JPMorgan Chase's upcoming healthcare partnerships, and how they compare to the bank's collaborations in 2019.
Geisinger Health CFO Dr. Kevin Roberts joins Yahoo Finance’s Anjalee Khemlani to discuss innovations in the healthcare industries at the JPMorgan Health Care Conference.
California could become the first state to make its own prescription drugs under a proposal announced by Gov. Gavin Newsom. Yahoo Finance's Seana Smith and Anjalee Khemlani discuss.
Practice Fusion Inc., an electronic health record provider acquired by Allscripts Healthcare Solutions Inc. in 2018, will pay $145 million to resolve criminal and civil allegations that it engaged in a kickback scheme encouraging physicians to prescribe opioids, the Justice Department said. Practice Fusion admitted that it solicited and received kickbacks from a maker of opioid products and other drugmakers in exchange for putting clinical decision support alerts in its health record software that led to more prescriptions for these products. Shares of Allscripts, which spent $100 million in cash to buy Practice Fusion, were down 0.17% in premarket trading on Tuesday and have dropped 25% over the last 52 weeks. The Health Care Sector Sector SPDR Fund , an exchange-traded fund, has climbed about 14% over the last year.
Wall Street slumped greatly to start the week. Is it a sign of the beginning of a correction? Bet on the top-ranked ETFs that are on sale.
Shares of Bausch Health Companies Inc. were up 0.3% in premarket trading on Tuesday after it announced the publication of late-stage trial data for an investigational eye therapy it is developing with Clearside Biomedical Inc. . Clearside's stock was up 9%. The experimental therapy, Xipere, is being tested as a treatment for macular edema associated with uveitis. The Phase 3 study, called the Peachtree Study, showed that about half of the patients taking the treatment had an improvement in visual acuity. Bausch's stock is up 17% over the last 52 weeks, while shares of Clearside have gained 161%. The Health Care Sector Sector SPDR Fund , an exchange-traded fund, has climbed about 14%.
Shares of NantHealth Inc. soared 56% in premarket trading on Tuesday after the company said it had developed an artificial intelligence software used to improve lung-cancer diagnoses. "With highly accurate tumor-region and lymphocyte detection, oncologists may better treat their patients," NantHealth CEO Dr. Patrick Soon-Shiong said in a news release. Earlier this month, NantHealth said it planned to sell its connected care business to Masimo Corp. for $47.2 million in cash. That deal is expected to close in the first quarter. NantHealth's stock is up 119% over the last 52 weeks, while the Health Care Sector Sector SPDR Fund , an exchange-traded fund, has gained 14%.
Virus fears affected stocks around the world as the China coronavirus continued to spread, with a fifth confirmed case in the U.S. China stocks fell hard.
Shares of AbbVie Inc. were up 2% in trading on Monday morning after the drugmaker said Allergan , which it is in the process of acquiring, plans to divest two therapies. Allergan's stock is up 1%. It is selling brazikumab, an experimental Crohn's disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé. The divestitures are required for AbbVie to move forward with the $63 billion Allergan acquisition, which is expected to close this quarter. AbbVie's stock is up 3% over the last 52 weeks, while Allergan's stock has gained 18% during the same time frame. The Health Care Select Sector SPDR Fund has climbed 15% over the last year.
Uber Technologies, Inc. (UBER) was muscling in on their territory. This reminds me of everyone buying stocks. The Russell 2000 rebalances, which makes the index more equally weighted compared to the S&P and NASDAQ.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
In an election year, some market segments and sector-related ETFs may perform poorly while others stand out as investors react to policy momentum among the presidential candidates. According to Dow Jones Market Data going back to 1928, the healthcare sector returned an average 7.9% and the technology sector returned an average 5.0% during the election year, compared to the S&P 500's 9.1% return. The healthcare sector is especially under the spotlight this time around as Democratic candidates propose major changes to how Americans receive health insurance and President Donald Trump eyed drug prices.
Shares of Abbott Laboratories were up 1% after the company reported sales increases across each of its four businesses in the fourth quarter of 2019. Net earnings were $1.05 billion, or 59 cents per share, in the fourth quarter, up from $654 million, or 37 cents per share, in the same quarter a year ago. Abbott said that adjusted earnings per share were $0.95 per share, compared with the FactSet consensus of $0.95. Total sales were up 7.1% to $8.3 billion, compared with the FactSet consensus of $8.2 billion. Medical device sales increased 9.7%, nutrition sales rose 5.2%, pharmaceutical sales were up 7.8%, and laboratory diagnostics sales rose by 8.4%. Sales of the company's MitraClip device, which is used in minimally invasive cardiovascular procedures, jumped 27% to $191 million. Abbott said it expects adjusted EPS of $3.55 to $3.65 in 2020. The FactSet consensus is $3.61. Abbott's stock has gained 25% over the last year. The SPDR Health Care Select Sector exchange-traded fund is up 16%, while the Dow Jones Industrial Average has gained about 18%.
Shares of Johnson & Johnson slipped 0.1% in premarket trading Wednesday, after the consumer products and drug giant reported a fourth-quarter profit that beat expectations but revenue that came up a bit shy. Net income rose to $4.01 billion, or $1.50 a share, from $3.04 billion, or $1.12 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew 4.6% to $1.88, above the FactSet consensus of $1.87. Sales rose 1.7% to $20.75 billion, just below the FactSet consensus of $20.80 billion. Consumer revenue increased 0.9% to $3.57 billion, below the FactSet consensus of $3.59 billion; pharmaceuticals sales grew 3.5% to $10.55 billion to top expectations of $10.43 billion; and medical device sales fell 0.5% to $6.63 billion to miss expectations of $6.69 billion. For 2020, the company expects net sales of $85.4 billion to $86.2 billion, surrounding the FactSet consensus of $85.52 billion. The stock has gained 0.4% over the past three months through Tuesday, while the SPDR Health Care Select Sector ETF has climbed 13.9% and the Dow Jones Industrial Average has advanced 9.0%.
UnitedHealth Group reported mixed fourth-quarter 2019 results wherein it breezed past the Zacks Consensus Estimate on earnings but lagged on revenues.
Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids. As part of the settlement, the company did not admit wrongdoing. According to a news release from the Attorney General's office, Endo will not employ or contract with sales reps in Oklahoma and will not pay for direct or indirect promotion of opioids. Endo has also settled similar opioid-related lawsuits with two counties in Ohio. Endo's stock has tumbled 52% over the last year. The Health Care Select Sector SPDR exchange-traded fund is up 17%.
Income-minded investors who are looking for better dividend growth opportunities can consider targeted exchange traded fund plays to hone in on potentially worthwhile areas, notably those in the healthcare ...
The healthcare sector has been a sure, but steady performer and a common safe haven sector when stocks head to the downside, but will future regulatory risks expose too much froth via overvaluation in ...
Traditional dividend havens such as utilities and real estate investment trusts are expected to continue that role, with yields in the 3% range this year. Those looking for more robust dividend growth should consider sectors such as health care and technology.
The S&P 500 continues its run in Market State 1, now at 14 consecutive days. Typically, it is a good sign to see the Nasdaq leading the S&P 500. When analyzing the market, and more specifically the S&P 500, it is always interesting to look at the strength of certain market sectors.
Abbott Laboratories disclosed Wednesday that Chief Financial Officer Brian Yoor has said he will retire, effective Feb. 29. He was named to his current position as executive vice president and CFO in February 2017. The drug and medical products company said it named Controller Robert Funck as CFO, effective March 1. The stock rose 0.4% in morning trading. It has rallied 26.2% over the past 12 months, while the SPDR Health Care Select Sector ETF has advanced 17.3% and the S&P 500 has climbed 26.1%.
Shares of Walgreens Boots Alliance Inc. fell 4% in premarket trading on Wednesday after the pharmacy chain missed first-quarter earnings expectations. Walgreens had net earnings of $845 million, or $0.95 a share, compared with $1.1 billion, or $1.18 a share, in the same quarter a year ago. Adjusted EPS was $1.37, against a FactSet consensus of $1.41. Sales increased 1.6% to $34.3 billion in the fiscal first quarter. The FactSet consensus was $34.6 billion. Retail pharmacy sales in the U.S. also rose 1.6%, driven by a 2.9% increase in pharmacy sales. U.S. retail sales, however, dropped 2.2% in the first quarter, compared to the same quarter a year ago. Walgreens reiterated guidance for adjusted EPS in 2020. The pharmacy chain has lately turned to partnerships, with brands like Jenny Craig, Kroger, and VillageMD, to shore up its business. "We are maintaining our outlook for the year despite a soft first quarter," Walgreens CEO Stefano Pessina said in a news release. Walgreens' stock has fallen 17% over the last year. The Health Care Select Sector SPDR Fund , an exchange-traded fund, is up 17% over the last year.